Understanding Immunotherapy: Types, Effects, and Success Rates in 2024

Immunotherapy is changing cancer treatment. It helps your body fight cancer cells.

But how does it work? What types are there? And how successful is it?

This guide answers these questions. We’ll explore immunotherapy’s types, effects, and success rates.

You’ll learn when doctors use it and its challenges. Let’s start with the basics.

What is Immunotherapy?

TL;DR:

• Immunotherapy boosts the body’s natural defenses to fight cancer

• It can lead to long-lasting remissions with fewer side effects

• Multiple types exist, including checkpoint inhibitors and CAR T-cell therapy

Immunotherapy is a groundbreaking approach to cancer treatment that harnesses the power of the body’s immune system. Unlike traditional cancer therapies that directly target cancer cells, immunotherapy works by enhancing or modifying the immune response to recognize and destroy cancer cells more effectively.

This innovative treatment has revolutionized cancer care, offering new hope for patients with previously difficult-to-treat cancers.

Examples of Immunotherapy

The success of immunotherapy in treating various types of cancer has been nothing short of remarkable. One of the most notable examples is the case of former U.S. President Jimmy Carter. In 2015, at the age of 91, Carter was diagnosed with metastatic melanoma that had spread to his brain and liver. He was treated with pembrolizumab, a checkpoint inhibitor, and radiation therapy. Remarkably, by December 2015, Carter announced that his brain scans showed no signs of cancer.

Another compelling example is the treatment of advanced non-small cell lung cancer (NSCLC). Historically, patients with advanced NSCLC had a poor prognosis, with five-year survival rates below 5%. However, the introduction of immunotherapy has dramatically changed this landscape. A study published in the Journal of Clinical Oncology in 2019 showed that patients with advanced NSCLC treated with pembrolizumab had a five-year survival rate of 23.2%, a significant improvement over traditional chemotherapy.

Immunotherapy has also shown promise in treating various other cancer types:

1. Bladder Cancer: The checkpoint inhibitor atezolizumab has shown effectiveness in treating advanced bladder cancer, with some patients experiencing complete remissions.
2. Hodgkin Lymphoma: Nivolumab has demonstrated high response rates in patients with relapsed or refractory Hodgkin lymphoma, offering a new option for those who have failed standard treatments.
3. Leukemia: CAR T-cell therapy has been particularly successful in treating certain types of leukemia, especially in pediatric patients with acute lymphoblastic leukemia (ALL).

Types of Immunotherapy

Immunotherapy encompasses a wide range of approaches, each with its unique mechanism of action. Understanding these different types is crucial for both healthcare providers and patients to make informed decisions about treatment options.

Checkpoint Inhibitors

Checkpoint inhibitors are arguably the most widely recognized form of immunotherapy. These drugs work by blocking proteins that act as “brakes” on the immune system, allowing immune cells to recognize and attack cancer cells more effectively.

The immune system has several checkpoints to prevent it from attacking healthy cells. Cancer cells often exploit these checkpoints to evade detection. Checkpoint inhibitors essentially “unmask” cancer cells, making them visible to the immune system.

Common checkpoint proteins targeted by these inhibitors include:

1. PD-1 (Programmed Death-1): PD-1 is a protein on T cells that helps keep these cells from attacking other cells in the body. When PD-1 binds to PD-L1 on a cell, it tells the T cell not to attack that cell. Some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack.
2. CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4): This protein also helps keep immune system responses in check. When CTLA-4 is blocked, it can boost the immune response against cancer cells.

Examples of FDA-approved checkpoint inhibitors include:

• Pembrolizumab (Keytruda) and Nivolumab (Opdivo) – PD-1 inhibitors

• Atezolizumab (Tecentriq) and Durvalumab (Imfinzi) – PD-L1 inhibitors

• Ipilimumab (Yervoy) – CTLA-4 inhibitor

These drugs have shown remarkable efficacy in treating various cancers, including melanoma, lung cancer, and bladder cancer. For instance, a study published in the New England Journal of Medicine in 2019 showed that pembrolizumab, when used as a first-line treatment for advanced non-small cell lung cancer, improved overall survival compared to chemotherapy.

CAR T-cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy represents a significant leap forward in personalized cancer treatment. This approach involves modifying a patient’s own T cells to better recognize and attack cancer cells.

The process of CAR T-cell therapy involves several steps:

1. Collection: T cells are collected from the patient’s blood through a process called leukapheresis.
2. Genetic Modification: The collected T cells are genetically engineered in a laboratory to produce chimeric antigen receptors (CARs) on their surface. These CARs are proteins that allow the T cells to recognize a specific antigen on tumor cells.
3. Expansion: The modified T cells are grown in large numbers in the laboratory.
4. Infusion: The CAR T cells are then infused back into the patient, where they can multiply and attack cancer cells.

CAR T-cell therapy has shown remarkable success in treating certain blood cancers. As of 2024, several CAR T-cell therapies have been approved by the FDA:

• Tisagenlecleucel (Kymriah): Approved for certain types of leukemia and lymphoma

• Axicabtagene ciloleucel (Yescarta): Approved for certain types of lymphoma

• Brexucabtagene autoleucel (Tecartus): Approved for mantle cell lymphoma and acute lymphoblastic leukemia

The success rates of CAR T-cell therapy in some cancers have been unprecedented. For example, in a clinical trial for children and young adults with acute lymphoblastic leukemia (ALL) who had exhausted all other treatment options, 83% achieved complete remission after receiving tisagenlecleucel.

Cancer Vaccines

Cancer vaccines represent another innovative approach in immunotherapy. Unlike traditional vaccines that prevent diseases, cancer vaccines are designed to treat existing cancers or prevent their recurrence. They work by stimulating the immune system to recognize and attack cancer cells more effectively.

There are two main types of cancer vaccines:

1. Preventive (or Prophylactic) Vaccines: These vaccines work by preventing cancer-causing infections. The most well-known example is the Human Papillomavirus (HPV) vaccine, which prevents infection with HPV types that can cause cervical, anal, and other cancers.
2. Treatment (or Therapeutic) Vaccines: These vaccines are designed to treat existing cancers by boosting the immune system’s ability to fight cancer cells.

While preventive vaccines like the HPV vaccine have been highly successful, treatment vaccines have faced more challenges. However, there have been some notable successes:

• Sipuleucel-T (Provenge): This was the first FDA-approved cancer treatment vaccine. It’s used to treat certain types of prostate cancer and has been shown to extend survival by several months in some patients.

• Bacillus Calmette-Guérin (BCG): While primarily known as a tuberculosis vaccine, BCG is also used as an immunotherapy for bladder cancer. It’s instilled directly into the bladder and has been shown to reduce the risk of bladder cancer recurrence.

Research is ongoing to develop more effective cancer treatment vaccines. For example, personalized cancer vaccines, which are tailored to the specific mutations in an individual’s tumor, are showing promise in clinical trials. A study published in Nature in 2020 reported that a personalized mRNA vaccine, when combined with a checkpoint inhibitor, showed promising results in patients with melanoma.

Monoclonal Antibodies

Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system’s attack on cancer cells. They are designed to bind to specific targets found on cancer cells.

The mechanism of action of monoclonal antibodies in cancer treatment can vary:

1. Direct action: Some monoclonal antibodies bind to specific antigens on cancer cells, marking them for destruction by the immune system.
2. Blocking growth signals: Some antibodies bind to receptors on cancer cells, blocking growth signals and preventing the cancer from growing.
3. Delivering radiation or chemotherapy: Some antibodies are linked to a radioactive particle or chemotherapy drug, delivering these treatments directly to cancer cells.

Several monoclonal antibodies have been approved by the FDA for cancer treatment:

• Rituximab (Rituxan): Used to treat certain types of lymphoma and leukemia

• Trastuzumab (Herceptin): Used to treat HER2-positive breast cancer

• Cetuximab (Erbitux): Used to treat certain types of colorectal cancer and head and neck cancer

• Bevacizumab (Avastin): Used to treat various cancers including colorectal, lung, and ovarian cancer

The efficacy of monoclonal antibodies can be significant. For example, the addition of trastuzumab to chemotherapy for HER2-positive breast cancer has been shown to reduce the risk of recurrence by 52% compared to chemotherapy alone.

Cytokines

Cytokines are small proteins that play a crucial role in controlling the growth and activity of immune system cells and blood cells. In cancer immunotherapy, cytokines are used to enhance the body’s immune response against cancer.

Two main types of cytokines are used in cancer treatment:

1. Interferons (IFNs): These cytokines help the immune system fight cancer and may slow the growth of cancer cells. Interferon-alpha has been used to treat several types of cancer, including melanoma and kidney cancer.
2. Interleukins (ILs): These cytokines help immune system cells grow and divide more quickly. Interleukin-2 (IL-2) has been used to treat kidney cancer and melanoma.

While cytokine therapy can be effective, it often causes severe side effects, which has limited its widespread use. However, research is ongoing to develop new cytokine therapies with improved efficacy and reduced toxicity.

For example, a study published in Nature in 2019 reported on a new type of engineered IL-2 that showed enhanced anti-tumor activity with reduced toxicity in animal models. This approach, if successful in human trials, could revitalize the use of cytokines in cancer immunotherapy.

How Immunotherapy Works

• Immunotherapy leverages the body’s immune system to fight cancer

• It enhances natural immune responses and helps identify cancer cells

• The treatment activates specific immune cells and targets tumor antigens

The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful invaders. In cancer treatment, immunotherapy harnesses this natural defense mechanism to combat malignant cells.

This approach differs significantly from traditional cancer treatments like chemotherapy or radiation, which directly attack cancer cells but often damage healthy cells in the process.

Activation of Immune Cells

Immunotherapy works by stimulating specific components of the immune system, particularly T-cells, to recognize and attack cancer cells more effectively. T-cells are a type of white blood cell that play a central role in cell-mediated immunity. They have the ability to recognize and destroy abnormal cells, including those that have become cancerous.

One key mechanism of immunotherapy is the activation of these T-cells.

This process involves several steps:

1. Antigen Presentation: Cancer cells often display unique proteins on their surface, known as tumor antigens. These antigens are presented to T-cells by specialized cells called antigen-presenting cells (APCs).
2. T-cell Activation: When a T-cell encounters its specific antigen, it becomes activated. This activation process is complex and involves multiple signaling pathways within the T-cell.
3. Proliferation and Differentiation: Activated T-cells multiply rapidly and differentiate into effector T-cells, which are capable of directly killing cancer cells, and memory T-cells, which provide long-term immunity.
4. Migration: Activated T-cells travel through the bloodstream to reach tumor sites throughout the body.
5. Tumor Cell Destruction: Upon reaching the tumor, effector T-cells release cytotoxic substances that destroy cancer cells.

The concept of immune memory is particularly important in cancer treatment. Memory T-cells, which are formed during the initial immune response, persist in the body long after the initial activation. These cells can quickly recognize and respond to the same tumor antigens if they reappear, potentially preventing cancer recurrence.

Recent studies have shown that patients with higher numbers of tumor-infiltrating T-cells often have better prognoses. For example, in a study of colorectal cancer patients, those with high levels of memory T-cells in their tumors had a 5-year survival rate of 72.5%, compared to 30.6% in patients with low levels.

Checkpoint Inhibitors: A Revolutionary Approach

One of the most successful forms of immunotherapy involves checkpoint inhibitors. These drugs work by blocking proteins that normally keep immune responses in check. By removing these “brakes” on the immune system, checkpoint inhibitors allow T-cells to mount a stronger attack against cancer cells.

The discovery of checkpoint inhibitors revolutionized cancer treatment and led to the 2018 Nobel Prize in Physiology or Medicine being awarded to James P. Allison and Tasuku Honjo. Their work on CTLA-4 and PD-1 checkpoint proteins, respectively, paved the way for new immunotherapy drugs that have shown remarkable success in treating various types of cancer.

For a deeper understanding of checkpoint inhibitors and their mechanisms, the book “The Breakthrough: Immunotherapy and the Race to Cure Cancer” by Charles Graeber provides an excellent, accessible overview of this field.

Targeting Cancer Cells

While activating immune cells is crucial, helping the immune system recognize cancer cells is equally important. Cancer cells often evolve mechanisms to evade immune detection, making them “invisible” to the body’s natural defenses. Immunotherapy aims to overcome this by enhancing the immune system’s ability to identify and target cancer cells specifically.

Several methods are employed to achieve this:

1. Monoclonal Antibodies: These are laboratory-produced molecules engineered to serve as substitute antibodies. They can enhance the immune system’s ability to recognize and respond to cancer cells. Some monoclonal antibodies are designed to bind to specific proteins on cancer cells, making them more visible to the immune system.
2. Cancer Vaccines: Unlike preventive vaccines, cancer vaccines are designed to treat existing cancers. They work by exposing the immune system to cancer antigens, training it to recognize and attack cells bearing these antigens.
3. Adoptive Cell Transfer: This involves removing immune cells from a patient, modifying them in the laboratory to enhance their cancer-fighting abilities, and then reinfusing them into the patient. CAR T-cell therapy is a prominent example of this approach.

The concept of tumor antigens is central to these targeting strategies. Tumor antigens are molecules expressed by cancer cells that can be recognized by the immune system. They can be proteins, carbohydrates, or other molecules that are either unique to cancer cells or are expressed at much higher levels in cancer cells compared to normal cells.

Types of Tumor Antigens

There are several types of tumor antigens:

1. Tumor-Specific Antigens (TSAs): These are unique to cancer cells and not found on normal cells. They often result from mutations in cancer cells.
2. Tumor-Associated Antigens (TAAs): These are present on both cancer cells and normal cells but are overexpressed in cancer cells.
3. Cancer-Testis Antigens: These are normally only expressed in germ cells of the testes but can be abnormally expressed in various cancer types.

The identification and characterization of tumor antigens have been crucial in developing targeted immunotherapies. For instance, the discovery of the HER2 protein as a tumor antigen in some breast cancers led to the development of trastuzumab (Herceptin), a monoclonal antibody that has significantly improved outcomes for HER2-positive breast cancer patients.

Recent research has shown that tumors with a higher mutational burden (and thus potentially more tumor-specific antigens) tend to respond better to immunotherapy. For example, a study published in the New England Journal of Medicine found that non-small cell lung cancer patients with high tumor mutational burden had a 1-year progression-free survival rate of 42.6% when treated with immunotherapy, compared to 13.2% for those with low tumor mutational burden.

For those interested in delving deeper into the complexities of tumor antigens and their role in immunotherapy, “The Molecular Basis of Cancer” by John Mendelsohn et al. provides a comprehensive overview of cancer biology, including detailed discussions on tumor immunology.

Benefits of Immunotherapy

• Long-lasting remissions improve cancer survival rates
• Fewer side effects enhance patient quality of life
• Combination potential amplifies treatment effectiveness

Long-lasting Remissions

Immunotherapy stands out for its ability to induce durable responses in cancer patients. This treatment approach can lead to long-term survival rates that surpass those of conventional therapies. The key lies in how immunotherapy works with the body’s natural defenses.

Unlike chemotherapy, which directly attacks cancer cells but can lose effectiveness over time, immunotherapy trains the immune system to recognize and combat cancer cells continuously. This ongoing vigilance can result in extended periods of remission or even complete eradication of cancer in some cases.

For example, in advanced melanoma, a type of skin cancer, long-term follow-up studies have shown remarkable results. A study published in the New England Journal of Medicine reported that 52% of patients treated with the immunotherapy drug pembrolizumab were alive after five years. This is a significant improvement compared to historical survival rates of less than 5% for advanced melanoma patients treated with conventional therapies.

Durability Across Cancer Types

The long-lasting effects of immunotherapy are not limited to melanoma. Other cancer types have also shown promising results:

1. Non-small cell lung cancer (NSCLC): Five-year survival rates for patients with advanced NSCLC treated with immunotherapy have reached up to 23%, compared to historical rates of about 5% with chemotherapy alone.
2. Bladder cancer: In a study of patients with advanced bladder cancer, 46% of those who responded to immunotherapy were still alive after three years.
3. Hodgkin lymphoma: Patients with relapsed or refractory Hodgkin lymphoma have shown remarkable responses to immunotherapy, with some studies reporting progression-free survival rates of over 80% at two years.

These extended survival rates highlight the potential of immunotherapy to transform cancer from an acute, life-threatening disease into a chronic, manageable condition for some patients.

Fewer Side Effects

One of the most significant advantages of immunotherapy is its generally milder side effect profile compared to traditional cancer treatments like chemotherapy and radiation. This difference stems from the targeted nature of immunotherapy, which primarily affects the immune system rather than attacking all rapidly dividing cells in the body.

Comparative Side Effect Profiles

To understand the impact on patient quality of life, let’s compare the side effects of immunotherapy to those of chemotherapy:

1. Hair loss: Common with chemotherapy, rare with immunotherapy.
2. Nausea and vomiting: Frequent and often severe with chemotherapy, less common and typically milder with immunotherapy.
3. Bone marrow suppression: A major concern with chemotherapy, leading to increased risk of infections and bleeding. Rare with immunotherapy.
4. Fatigue: Can be severe with both treatments, but often less pronounced with immunotherapy.

While immunotherapy can cause unique side effects such as autoimmune reactions, these are generally less frequent and more manageable than the systemic toxicities associated with chemotherapy.

Quality of Life Improvements

The reduced side effect burden of immunotherapy translates to significant quality of life improvements for many patients. A study published in the Journal of Clinical Oncology found that patients receiving immunotherapy for advanced lung cancer reported better physical functioning and fewer symptoms compared to those on chemotherapy.

Patients on immunotherapy often maintain their ability to work, engage in social activities, and perform daily tasks with less interruption. This improved functionality can have profound psychological benefits, reducing the emotional toll of cancer treatment.

Combination Potential

The ability of immunotherapy to work synergistically with other cancer treatments represents a significant advantage. By combining immunotherapy with traditional therapies or targeted treatments, oncologists can often achieve better outcomes than with single-modality approaches.

Enhancing Traditional Treatments

Immunotherapy can amplify the effects of chemotherapy and radiation therapy in several ways:

1. Sensitization: Immunotherapy can make cancer cells more vulnerable to the effects of chemotherapy and radiation.
2. Abscopal effect: In some cases, radiation therapy combined with immunotherapy has led to tumor shrinkage not only at the irradiated site but also in distant metastases.
3. Overcoming resistance: Some tumors that have become resistant to chemotherapy or targeted therapies may still respond when these treatments are combined with immunotherapy.

Successful Combination Therapies

Several combination approaches have shown promising results in clinical trials:

1. Melanoma: The combination of ipilimumab (an immunotherapy drug) with nivolumab (another immunotherapy) has shown superior outcomes compared to either drug alone in advanced melanoma, with 5-year survival rates reaching 52%.
2. Non-small cell lung cancer: Adding pembrolizumab to chemotherapy improved overall survival in patients with metastatic NSCLC, leading to FDA approval of this combination as first-line treatment.
3. Renal cell carcinoma: The combination of axitinib (a targeted therapy) with pembrolizumab or avelumab (immunotherapies) has become a standard first-line treatment for advanced kidney cancer, showing improved progression-free survival compared to previous standards of care.

These successful combinations demonstrate the potential of immunotherapy to enhance and complement existing treatment modalities, offering new hope for patients with previously limited options.

Precision Medicine Approach

Immunotherapy aligns closely with the principles of precision medicine, offering a more tailored approach to cancer treatment. This personalized strategy can lead to improved outcomes and reduced unnecessary treatments.

Biomarker-Guided Treatment

The efficacy of immunotherapy often correlates with specific biomarkers. For example:

1. PD-L1 expression: Higher levels of PD-L1 on tumor cells often predict better responses to checkpoint inhibitors in certain cancers.
2. Tumor Mutational Burden (TMB): Cancers with high TMB tend to respond better to immunotherapy due to increased neoantigen production.
3. Microsatellite Instability (MSI): Tumors with high MSI are often more responsive to immunotherapy, leading to FDA approval of pembrolizumab for all MSI-high cancers regardless of origin.

By using these biomarkers, oncologists can better predict which patients are likely to benefit from immunotherapy, sparing others from potential side effects of ineffective treatments.

Adaptive Treatments

Immunotherapy allows for adaptive treatment strategies. As the immune response evolves, treatments can be adjusted based on ongoing monitoring of immune markers and tumor characteristics. This dynamic approach contrasts with the more rigid protocols of traditional chemotherapy regimens.

Potential for Cure in Advanced Cancers

Perhaps the most exciting benefit of immunotherapy is its potential to induce complete and lasting remissions in some patients with advanced cancers, effectively amounting to a cure.

While the term “cure” is used cautiously in oncology, long-term follow-up studies of immunotherapy patients have revealed a subset who remain cancer-free for many years after treatment discontinuation. This phenomenon has been observed in melanoma, lung cancer, and other tumor types.

A landmark study published in the Journal of Clinical Oncology followed patients with advanced melanoma treated with ipilimumab. Among those who achieved complete remission, 92% remained disease-free after five years, with some patients maintaining remission for over a decade.

This curative potential in advanced disease settings represents a paradigm shift in cancer treatment, offering hope where previously there was little.

References: 
https://www.nejm.org/doi/full/10.1056/NEJMoa1504627 
https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects 
https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief 
https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects 
https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects 
https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief 
https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects 
https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief 
https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects 
https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief 
https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects 
https://www.nejm.org/doi/full/10.1056/NEJMoa1504627

Side Effects of Immunotherapy

TL;DR:

• Immunotherapy side effects differ from chemotherapy
• Common side effects include fatigue, skin reactions, and flu-like symptoms
• Rare but serious complications can occur, requiring close monitoring

Common Side Effects

Immunotherapy triggers the immune system to fight cancer cells, but this activation can lead to side effects. These effects often differ from those experienced with chemotherapy.

Fatigue is one of the most common side effects of immunotherapy. Unlike the extreme exhaustion often associated with chemotherapy, immunotherapy-related fatigue is typically milder. However, it can persist for longer periods, sometimes lasting months after treatment ends.

Skin reactions are another frequent side effect. These can range from mild rashes to severe itching. In some cases, patients may develop vitiligo, a condition where the skin loses its pigmentation in patches. While these skin issues can be uncomfortable, they’re often manageable with topical treatments.

Flu-like symptoms are also common, particularly in the days following treatment. Patients may experience fever, chills, and body aches. These symptoms usually subside within a few days but can be distressing for patients.

Gastrointestinal issues, such as diarrhea, nausea, and loss of appetite, can occur. While these symptoms are also common in chemotherapy, they tend to be less severe with immunotherapy.

Here I’m comparing the frequency and severity of common side effects between immunotherapy and chemotherapy:

Side Effect	Immunotherapy Frequency	Immunotherapy Severity	Chemotherapy Frequency	Chemotherapy Severity
Fatigue	Common	Mild to Moderate	Very Common	Severe
Skin Reactions	Common	Mild to Severe	Less Common	Mild
Flu-like Symptoms	Common	Mild to Moderate	Less Common	Mild
Gastrointestinal Issues	Common	Mild to Moderate	Very Common	Moderate to Severe

This table provides a concise comparison of the side effects associated with immunotherapy and chemotherapy, highlighting their frequency and severity.

Comparison to Chemotherapy Side Effects

Immunotherapy side effects are generally considered less severe than those of chemotherapy. Hair loss, a hallmark of chemotherapy, is rare with immunotherapy. Similarly, the risk of infections due to a weakened immune system is lower with immunotherapy.

However, immunotherapy side effects can be more unpredictable and may occur at any time during or after treatment. This unpredictability can be challenging for patients and healthcare providers.

Managing Side Effects

Effective management of immunotherapy side effects is crucial for patient well-being and treatment success. Many side effects can be managed with supportive care and medication.

For fatigue, a combination of rest and light exercise can be beneficial. Studies have shown that moderate physical activity can help reduce cancer-related fatigue. The American Cancer Society recommends 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity activity per week for cancer patients, if approved by their healthcare provider.

Skin reactions often respond well to topical corticosteroids. For more severe cases, oral steroids may be necessary. It’s important for patients to protect their skin from sun exposure and use gentle, fragrance-free skincare products.

Flu-like symptoms can be managed with over-the-counter pain relievers and fever reducers. Staying hydrated is crucial, especially if diarrhea is present.

Importance of Communication with Healthcare Providers

Open and frequent communication between patients and their healthcare team is vital. Patients should report any new symptoms promptly, no matter how minor they may seem. Early intervention can prevent side effects from becoming more severe and potentially disrupting treatment.

Healthcare providers may use a grading system to assess the severity of side effects. This system, often based on the Common Terminology Criteria for Adverse Events (CTCAE), helps guide treatment decisions and determines whether immunotherapy should be paused or discontinued.

Rare but Serious Complications

While most immunotherapy side effects are manageable, some patients may experience rare but serious complications. These are often related to autoimmune reactions, where the activated immune system attacks healthy organs.

Autoimmune reactions can affect various organs, including the lungs (pneumonitis), liver (hepatitis), thyroid gland (thyroiditis), and pituitary gland (hypophysitis). In rare cases, these reactions can be life-threatening if not recognized and treated promptly.

Myocarditis, an inflammation of the heart muscle, is a particularly concerning complication.

The incidence of myocarditis in patients undergoing immunotherapy, particularly with immune checkpoint inhibitors (ICIs), varies between 0.27% and 1.14%, with the incidence being higher in patients receiving dual ICI therapy. This condition, although rare, is severe and can be fatal if not detected and managed promptly. The risk of myocarditis increases when ICIs are combined with other cardiotoxic agents or in patients with underlying autoimmune diseases​ (SpringerLink)​​ (MDPI)​​ (American College of Cardiology)​.

Monitoring Protocols and Early Intervention

To manage these potential complications, healthcare providers implement strict monitoring protocols. These may include:

1. Regular blood tests to check liver function, thyroid hormones, and other markers of organ function.
2. Periodic chest X-rays or CT scans to detect lung inflammation.
3. Cardiac monitoring, especially in patients at high risk for heart complications.

Early intervention is key to managing serious complications. Treatment often involves high-dose corticosteroids to suppress the overactive immune response. In some cases, immunotherapy may need to be temporarily or permanently discontinued.

Long-term Effects and Quality of Life

While immunotherapy often has fewer immediate side effects than chemotherapy, its long-term impact on quality of life is still being studied. Some patients experience persistent fatigue or develop chronic autoimmune conditions as a result of treatment.

A study published in the Journal of Clinical Oncology found that melanoma patients treated with checkpoint inhibitors reported better health-related quality of life compared to those receiving chemotherapy. However, more research is needed to fully understand the long-term effects across different cancer types and immunotherapy regimens.

Emerging Research on Side Effect Management

Researchers are continually working to improve side effect management in immunotherapy. One promising area is the use of biomarkers to predict which patients are more likely to experience severe side effects.

For example, a study published in Nature Medicine identified specific gut microbiome signatures associated with a higher risk of colitis in patients receiving checkpoint inhibitors. This could lead to personalized prevention strategies, such as targeted probiotics or dietary interventions.

Another area of research focuses on combining immunotherapy with other treatments to enhance efficacy while minimizing side effects. For instance, combining checkpoint inhibitors with targeted therapies has shown promise in some cancer types, potentially allowing for lower doses and fewer side effects.

Immunotherapy Success Rates

TL;DR:

• Immunotherapy success varies by cancer type and stage

• Biomarkers and tumor characteristics affect response rates

• Long-term survival data shows promising results for some cancers

Overall Response Rates

Immunotherapy has shown varied success rates across different cancer types and stages. Recent data from clinical trials and real-world studies provide insights into its effectiveness.

For advanced melanoma, checkpoint inhibitors have demonstrated remarkable results. A study published in the New England Journal of Medicine in 2019 reported a 5-year overall survival rate of 52% for patients treated with ipilimumab plus nivolumab. This is a significant improvement compared to historical survival rates of less than 10% for advanced melanoma patients.

In non-small cell lung cancer (NSCLC), immunotherapy has also shown promising results. A 2020 review in the Journal of Clinical Oncology reported overall response rates ranging from 14% to 20% for PD-1 inhibitors used as monotherapy in previously treated NSCLC patients.

Success rates vary significantly across cancer types. For example:

• Bladder cancer: About 20-25% of patients respond to PD-1/PD-L1 inhibitors

• Triple-negative breast cancer: Response rates around 15-20% with checkpoint inhibitors

• Colorectal cancer: Generally low response rates (5-10%) except in patients with high microsatellite instability (MSI-H), where rates can reach 30-40%

Response Rates by Cancer Stage

Immunotherapy effectiveness often correlates with cancer stage. Early-stage cancers typically show higher response rates. For instance, in stage III melanoma, adjuvant immunotherapy has shown 3-year relapse-free survival rates of up to 63%.

In contrast, metastatic cancers generally have lower response rates but can still see significant improvements compared to traditional therapies. A 2021 meta-analysis in JAMA Oncology found that first-line immunotherapy in metastatic NSCLC improved overall survival by 27% compared to chemotherapy.

Factors Affecting Success

Several factors influence immunotherapy success rates. Understanding these can help predict which patients are more likely to benefit from treatment.

Biomarkers Predicting Response

Biomarkers play a crucial role in predicting immunotherapy response. Some key biomarkers include:

1. PD-L1 Expression: Higher levels of PD-L1 on tumor cells often correlate with better response to PD-1/PD-L1 inhibitors. However, this isn’t universally true for all cancer types.
2. Tumor Mutational Burden (TMB): Cancers with high TMB tend to respond better to immunotherapy. A study in Nature Medicine found that patients with high TMB had significantly improved survival rates across multiple cancer types when treated with immunotherapy.
3. Microsatellite Instability (MSI): Tumors with high MSI are often more responsive to immunotherapy. This led to the FDA’s approval of pembrolizumab for any solid tumor with high MSI, regardless of cancer type.

Dr. Padmanee Sharma, an immunotherapy expert at MD Anderson Cancer Center, states:

“Biomarkers are crucial in guiding immunotherapy decisions. They help us identify which patients are most likely to benefit, potentially sparing others from unnecessary treatments and side effects.”

Dr. Padmanee Sharma, immunotherapy expert at MD Anderson Cancer Center

‘Hot’ vs ‘Cold’ Tumors

The concept of ‘hot’ and ‘cold’ tumors is critical in understanding immunotherapy success rates.

‘Hot’ tumors are characterized by:
• High levels of tumor-infiltrating lymphocytes (TILs)
• Increased expression of immune-related genes
• Generally higher response rates to immunotherapy

‘Cold’ tumors, conversely, have:
• Few TILs
• Low expression of immune-related genes
• Generally lower response rates to immunotherapy

Dr. Thomas Gajewski, from the University of Chicago, explains:

“Converting ‘cold’ tumors to ‘hot’ ones is a major focus of current immunotherapy research. Combination therapies and novel approaches are being explored to achieve this.”

Dr. Thomas Gajewski, The University of Chicago

Long-term Survival Data

Long-term survival data for immunotherapy patients has been particularly encouraging for certain cancer types.

In advanced melanoma, a landmark study published in the New England Journal of Medicine in 2022 reported a 10-year overall survival rate of 21% for patients treated with ipilimumab. This is remarkable considering the historical 5-year survival rate for advanced melanoma was less than 10%.

For NSCLC, long-term data is also promising. A 2021 study in the Journal of Clinical Oncology found that patients with advanced NSCLC treated with pembrolizumab had a 5-year overall survival rate of 23.2%, compared to 15.5% for those treated with chemotherapy.

Comparing immunotherapy to traditional treatments:

• Melanoma: 5-year survival rates improved from <10% with chemotherapy to >50% with combination immunotherapy

• NSCLC: 5-year survival rates increased from about 5% with chemotherapy to >20% with immunotherapy in some studies

• Bladder cancer: 5-year survival rates for advanced disease improved from about 5% to 20-25% with immunotherapy

Dr. James Allison, Nobel laureate and pioneer in cancer immunotherapy, notes:

“The long-term survival data we’re seeing with immunotherapy is unprecedented. We’re not just extending life by a few months; we’re seeing durable responses that last years in some patients.”

Dr. James Allison, Nobel laureate and pioneer in cancer immunotherapy

These long-term survival statistics address the often-asked question: “What is life expectancy after immunotherapy?” While it varies by cancer type and individual factors, immunotherapy has significantly improved life expectancy for many patients with advanced cancers.

Regarding other frequently asked questions:

1. “Can you live longer with immunotherapy?” Yes, many studies have shown improved overall survival with immunotherapy compared to traditional treatments for various cancer types.
2. “Can cancer grow while on immunotherapy?” Yes, it’s possible. Some patients experience “pseudoprogression,” where tumors appear to grow initially but then shrink. However, true progression can also occur in non-responders.
3. “How successful is immunotherapy for cancer?” Success varies widely depending on cancer type, stage, and individual factors. While some cancers show high response rates (>50% in some cases), others have lower rates (<10% for some types).

References: 
https://lombardi.georgetown.edu/news-release/advanced-melanoma-survival-improves-significantly-when-immunotherapy-is-given-before-targeted-therapy/ 
https://www.cancerresearch.org/cancer-types/melanoma 
https://www.curemelanoma.org/about-melanoma/melanoma-staging/melanoma-survival-rates 
https://www.dana-farber.org/newsroom/news-releases/2021/survival-benefits-of-immunotherapy-combination-persist-for-more-than-six-years-in-patients-with-advanced-melanoma 
https://www.mskcc.org/news/changing-melanoma-landscape-how-research-has-improved-outlook-people-advanced-disease

When is Immunotherapy Used?

TL;DR:

• Immunotherapy is used at various cancer stages, from early to advanced
• It can be a first-line treatment, adjuvant therapy, or salvage option
• Patient eligibility depends on cancer type, biomarkers, and overall health

First-line Treatment

Immunotherapy has become the initial treatment choice for several cancers. This shift represents a significant change in cancer care. Doctors now consider immunotherapy before traditional methods like chemotherapy or radiation.

In advanced melanoma, immunotherapy is the standard first-line treatment. The PD-1 inhibitors pembrolizumab and nivolumab have shown remarkable results. A study published in the New England Journal of Medicine in 2019 reported a 5-year overall survival rate of 43% for patients with advanced melanoma treated with pembrolizumab. This is a stark improvement from the historical 5-year survival rate of less than 10% for advanced melanoma patients.

Non-small cell lung cancer (NSCLC) is another area where immunotherapy shines as first-line treatment. For patients with high PD-L1 expression (≥50%), pembrolizumab monotherapy is now the preferred option. The KEYNOTE-024 trial showed that pembrolizumab improved overall survival compared to platinum-based chemotherapy in these patients.

Biomarker-driven Decision Making

The decision to use immunotherapy as first-line treatment often relies on biomarkers. PD-L1 expression is a key factor in NSCLC. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status guides treatment in colorectal and other cancers. These biomarkers help identify patients most likely to benefit from immunotherapy.

For those interested in diving deeper into biomarker-driven immunotherapy decisions, the book “Predictive Biomarkers in Oncology” by Badve and Kumar provides an excellent overview of the field.

Advanced or Metastatic Cancer

Immunotherapy plays a crucial role in treating advanced or metastatic cancers. It offers hope where traditional treatments may have limited efficacy.

In metastatic triple-negative breast cancer, the combination of atezolizumab and nab-paclitaxel has shown promise. The IMpassion130 trial demonstrated improved progression-free survival in PD-L1-positive patients. This led to FDA approval of this combination for metastatic triple-negative breast cancer.

Salvage Therapy Concept

Salvage therapy refers to treatment given after standard treatments have failed. Immunotherapy has emerged as a valuable salvage option for many cancers.

In classical Hodgkin lymphoma, PD-1 inhibitors like nivolumab and pembrolizumab have shown remarkable efficacy as salvage therapy. A study published in The Lancet Oncology in 2019 reported an overall response rate of 69% with nivolumab in patients who had failed autologous stem cell transplantation and brentuximab vedotin.

Adjuvant Therapy

Adjuvant therapy aims to prevent cancer recurrence after primary treatment. Immunotherapy has made significant inroads in this area.

In melanoma, adjuvant immunotherapy has become standard practice. The CheckMate 238 trial showed that adjuvant nivolumab improved recurrence-free survival compared to ipilimumab in stage III or IV melanoma patients who had undergone complete resection.

Pembrolizumab is approved as adjuvant therapy for stage III melanoma based on the KEYNOTE-054 trial. This study showed a 43% reduction in the risk of recurrence or death compared to placebo.

Emerging Adjuvant Applications

Research is ongoing to expand the use of adjuvant immunotherapy. Promising areas include:

1. Non-small cell lung cancer: The PACIFIC trial showed improved overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.
2. Renal cell carcinoma: The KEYNOTE-564 trial is investigating pembrolizumab as adjuvant therapy.
3. Bladder cancer: The IMvigor010 trial is studying atezolizumab in this setting.

For a comprehensive review of adjuvant immunotherapy, “Principles of Cancer Biotherapy” by Oldham and Dillman is an excellent resource.

Neoadjuvant Setting

Immunotherapy before surgery (neoadjuvant) is an exciting area of research. Early results are promising in several cancers.

In non-small cell lung cancer, neoadjuvant nivolumab plus chemotherapy showed a significant improvement in pathological complete response compared to chemotherapy alone in the CheckMate 816 trial.

Melanoma is another focus of neoadjuvant immunotherapy research. The OpACIN-neo trial showed that neoadjuvant ipilimumab plus nivolumab led to high pathological response rates in stage III melanoma.

Maintenance Therapy

Immunotherapy as maintenance treatment aims to prolong remission after initial therapy. This approach is gaining traction in several cancers.

In advanced ovarian cancer, PARP inhibitors like olaparib have shown efficacy as maintenance therapy. The SOLO-1 trial demonstrated significantly improved progression-free survival with olaparib maintenance in BRCA-mutated ovarian cancer.

Immunotherapy maintenance is being explored in other cancers, including:

1. Non-small cell lung cancer: The PACIFIC trial used durvalumab as maintenance therapy.
2. Bladder cancer: The JAVELIN Bladder 100 trial investigated avelumab maintenance.
3. Renal cell carcinoma: The KEYNOTE-426 trial explored pembrolizumab plus axitinib followed by maintenance.

For those interested in the evolving landscape of maintenance immunotherapy, “Cancer Immunotherapy Principles and Practice” by Butterfield, Kaufman, and Marincola provides an in-depth exploration of this topic.

Challenges in Immunotherapy

TL;DR:

• Immunotherapy faces hurdles in cancer resistance and treatment evasion

• High costs and limited access restrict widespread adoption

• Predicting patient response remains a significant challenge

Resistance Mechanisms

Immunotherapy has shown remarkable success in treating various cancers. However, some tumors develop resistance, limiting its effectiveness. This resistance occurs through complex biological processes.

One primary resistance mechanism is the downregulation of tumor antigens. Cancer cells can reduce the expression of proteins that the immune system recognizes as foreign. This makes them less visible to immune cells, allowing them to escape detection and destruction.

Another mechanism involves the upregulation of immune checkpoint molecules. These molecules act as “off switches” for immune cells. By increasing their expression, cancer cells can effectively shut down the immune response, even in the presence of immunotherapy drugs.

Studies have shown that up to 60% of patients may develop resistance to checkpoint inhibitors over time, highlighting the need for ongoing research to overcome these challenges.

Ongoing Research to Overcome Resistance

Researchers are exploring several strategies to combat immunotherapy resistance:

1. Combination Therapies: By combining different immunotherapy approaches or adding targeted therapies, researchers aim to attack cancer from multiple angles. For example, combining PD-1 inhibitors with CTLA-4 inhibitors has shown improved responses in melanoma patients.
2. Epigenetic Modulation: Some studies focus on altering gene expression patterns in cancer cells to make them more susceptible to immune attack. Drugs that target epigenetic regulators, such as histone deacetylase inhibitors, are being investigated.
3. Personalized Neoantigen Vaccines: These vaccines are designed to target specific mutations in a patient’s tumor, potentially overcoming antigen loss resistance.
4. Targeting the Tumor Microenvironment: Efforts are underway to modify the area surrounding tumors, making it more conducive to immune cell infiltration and activation.

Cost and Accessibility

The high cost of immunotherapy treatments presents a significant barrier to widespread adoption. Many immunotherapy drugs come with price tags exceeding $100,000 per year of treatment.

This financial burden not only affects individual patients but also strains healthcare systems globally. In the United States, for instance, the average out-of-pocket cost for patients on immunotherapy can range from $3,000 to $5,000 per month, even with insurance coverage.

The issue of accessibility extends beyond just cost. Geographic disparities in healthcare infrastructure and expertise can limit access to immunotherapy treatments, particularly in rural or underserved areas.

Efforts to Improve Access

Several initiatives are underway to address these challenges:

1. Drug Price Negotiations: Some countries are implementing policies to negotiate drug prices directly with pharmaceutical companies. For example, the UK’s National Institute for Health and Care Excellence (NICE) has successfully negotiated lower prices for several immunotherapy drugs.
2. Patient Assistance Programs: Many pharmaceutical companies offer programs to help patients cover the costs of treatment. However, these programs often have strict eligibility criteria and may not be sustainable long-term solutions.
3. Biosimilars Development: As patents expire on original immunotherapy drugs, the development of biosimilars (similar versions of biologic drugs) could potentially lower costs. However, the complex nature of these drugs makes creating exact copies challenging.
4. Telemedicine and Mobile Health Units: To address geographic disparities, some healthcare systems are implementing telemedicine consultations with immunotherapy experts and mobile health units to bring treatments to remote areas.
5. Value-Based Pricing Models: Some healthcare systems are exploring pricing models where payment is tied to treatment outcomes, potentially reducing costs for less effective treatments.

Identifying Suitable Patients

Predicting which patients will respond to immunotherapy remains a significant challenge. While some patients experience dramatic and lasting responses, others show no benefit or may even experience severe side effects.

This unpredictability stems from the complex interplay between the immune system, tumor biology, and individual patient characteristics. Factors such as tumor mutational burden, presence of specific biomarkers, and the composition of the gut microbiome can all influence treatment response.

Development of Better Biomarkers and Diagnostic Tools

Researchers are working on several fronts to improve patient selection for immunotherapy:

1. PD-L1 Expression: While PD-L1 levels in tumors are currently used as a biomarker, its predictive value varies across cancer types. Researchers are exploring more nuanced ways to interpret PD-L1 expression patterns.
2. Tumor Mutational Burden (TMB): High TMB has been associated with better responses to immunotherapy in some cancers. Efforts are underway to standardize TMB measurement and interpretation across different cancer types.
3. Immune Cell Infiltration: Techniques to assess the presence and activity of tumor-infiltrating lymphocytes (TILs) are being refined to better predict immunotherapy response.
4. Circulating Tumor DNA (ctDNA): Analysis of ctDNA in blood samples could provide a less invasive way to monitor treatment response and detect resistance early.
5. Microbiome Analysis: Emerging research suggests that the composition of gut bacteria may influence immunotherapy response. Studies are exploring how to use this information for patient selection.
6. Artificial Intelligence: Machine learning algorithms are being developed to integrate multiple biomarkers and clinical data points to create more accurate prediction models.

Ethical Considerations

As these predictive tools become more sophisticated, ethical questions arise. How should we balance the potential benefits of treatment against the risk of side effects when predictions are not 100% accurate? How do we ensure equitable access to these diagnostic tools?

These challenges in immunotherapy – resistance, cost, and patient selection – highlight the complexity of cancer treatment. They also underscore the need for continued research, innovative approaches, and collaborative efforts across the scientific and medical communities. As we address these hurdles, we move closer to realizing the full potential of immunotherapy in cancer treatment.

The Future of Cancer Treatment

Immunotherapy has revolutionized cancer care, offering new hope for patients. It harnesses the body’s immune system, provides long-lasting remissions, and often has fewer side effects than traditional treatments. While challenges like resistance and cost exist, ongoing research promises to expand its effectiveness and accessibility.

How might immunotherapy impact your approach to cancer treatment?

Consider discussing this innovative therapy with your oncologist to explore its potential benefits for your specific situation. Remember, staying informed about the latest advancements in cancer care is crucial for making the best decisions for your health.

Stay Informed with Our Oncology Insights Newsletter!

Join our community of readers who receive the latest updates in oncology, expert insights, practical tips, and inspirational stories delivered straight to their inbox.

• Cutting-Edge Research: Stay updated with the latest advancements in cancer research and treatments.
• Expert Advice: Get practical tips and advice from leading oncologists and healthcare professionals.
• Inspiring Stories: Read powerful stories from cancer survivors and their journeys.
• Exclusive Content: Access special resources, study guides, and event invitations only available to our subscribers.

Subscribe Now